Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

594

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

November 30, 2028

Conditions

Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

DRUG

611

611 subcutaneous (SC) injection

DRUG

Placebo

placebo Q2W, subcutaneous (SC) injection

Trial Locations (4)

China-Japan Friendship Hospital, Beijing

Jiangsu Province Hospital, Nanjing

ZheJiang Provincial People's Hospital, Hangzhou

Shenzhen People's Hospital, Shenzhen

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY